Cannabis and Parkinson’s Disease: What a New Evidence Review Shows
A recent systematic review evaluated cannabis sativa Parkinsons motor symptoms and found Grade A evidence indicating no motor benefit. This review clarifies cannabis sativa's role in Parkinson's motor symptom treatment. It highlights the need for careful…
Insights on Cannabinoid Exposure in Substance Use Disorders
This 2026 review on cannabinoid exposure substance use disorders analyzes 97 studies with over 41,000 participants. It finds cannabinoids offer short-term symptom relief but lack durable efficacy for abstinence or relapse prevention. The evidence guides…
Cannabinoids in Substance Use Disorders: What a New Systematic Review Actually Found
Cannabinoids and substance use disorders were the focus of a 2026 systematic review spanning 97 studies and nearly 42,000 participants. The review found cannabinoids more often relieved short-term symptoms like craving and withdrawal than they improved…
Cannabis Science Evidence Report: Systematic Review and Meta-Analysis
A comprehensive systematic review and meta-analysis has investigated the prevalence of cannabis use and cannabis use disorder in individuals with early-onset psychosis. The study's findings have significant implications for clinicians and patients…
Cannabinoids in Autism, Fragile X, and Rett: What a New Systematic Review Found
A new cannabinoids pediatric autism review examined cannabinoid-based products in autism, Fragile X syndrome, and Rett syndrome. The review found possible behavioral and seizure signals but the evidence remains limited. This systematic review highlights…
GLP-1 Weight Loss Drugs: Male Fertility Safety Evidence
GLP-1 receptor agonist male fertility safety is supported by current evidence showing no adverse effects on reproductive function. Studies indicate these drugs may improve fertility outcomes through metabolic benefits. This reassures clinicians and…
Clinical Evidence of Tirzepatide’s Cardiometabolic Benefits in Obesity
Tirzepatide cardiometabolic benefits extend beyond weight loss in obese non-diabetic adults. Clinical trials demonstrate improvements in blood pressure, lipid profiles, and inflammation. This evidence supports tirzepatide as a metabolic intervention…
GLP-1 Receptor Agonists: Clinical Evidence and Uses
GLP-1 receptor agonists clinical safety is crucial for effective diabetes and obesity treatment. These medications regulate blood sugar and appetite with proven benefits. Understanding their safety profile helps optimize patient outcomes.
Cannabis Use Disorder Strongly Linked to Major Depression, New Review Finds
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthResearchTHCCannabis Use DisorderDepressionSafetyNeurology Why This Matters Clinicians treating patients…
Clinical Evidence on GLP-1 Receptor Agonists and Hair Loss
GLP-1 receptor agonist hair loss is a recognized adverse effect linked to rapid weight loss and metabolic changes. Clinical evidence shows this hair loss is typically reversible and related to telogen effluvium. Understanding this helps clinicians…